Antipsychotics use in the community of Thessaloniki, Greece
Abstract
Background/Aim. Under the current financial crisis in Greece, an effort has been made by the Greek health authorities to encourage generic prescribing, in order to lower medicinal cost. The purpose of this work was to study antipsychotics use, and to calculate utilization of generics in antipsychotics sales in a sample from the medicines market of Thessaloniki, the second largest city in Greece. Methods. A sample of antipsychotics registered sales was collected using the new Electronic Health Records that have been applied in pharmacies during the last years in Greece. The sample corresponded to a small amount of sales from the market of Thessaloniki during the period July 2014–June 2015, including only community and no hospital sales. All brand names (prototype and generics) of antipsychotics and their relative ratios in the sales were estimated, and the percentage of generics in the sale of each medicine was calculated. The amount of medicines was estimated in Defined Daily Doses (DDDs) of the reference/prototype drug and its generics. Results. Olanzapine, quetiapine, haloperidol and risperidone sales corresponded to 77% of total antipsychotics sales with percentages of sales 25%, 19%, 19% and 14% respectively. The percentage of sales of other antipsychotics was 7% for amisulpride, 6% for aripiprazole, 4% for ziprasidone and 3% for clozapine. Generic use corresponded to 41% of total sales of antipsychotic drugs (10.884 DDDs out of 26.433 DDDs). Concerning second generation antipsychotics, generic use was high for amisulpride, olanzapine, risperidone and quetiapine. Conclusion. In the study sample, second generation antipsychotics corresponded to 78% of sales in the community of Thessaloniki. Haloperidol utilization was also notable. Considering Greek practices, the percentage of generics in antipsychotics sales was very high even for some of the newest antipsychotics.
References
References
Tsiantou V, Zavras D, Kousoulakou H, Geitona M, Kyriopoulos J. Generic medicines: Greek physicians' perceptions and pre-scribing policies. J Clin Pharm Ther 2009; 34(5): 547–54.
Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al. Use of Generics: A Critical Cost Containment Measure for All Healthcare Professionals in Europe? Pharmaceuticals (Basel) 2010; 3(8): 2470–94.
Dunne SS, Dunne CP. What do people really think of generic medicines?, A systematic review and critical appraisal of litera-ture on stakeholder perceptions of generic drugs. BMC Med 2015; 13: 173.
Hamann J, Mendel R, Kissling W, Leucht S. Psychiatrists' decision making between branded and generic drugs. Eur Neuropsychopharmacol 2013; 23(7): 686–90.
Karampli E, Souliotis K, Polyzos N, Kyriopoulos J, Chatzaki E. Pharmaceutical innovation: Impact on expenditure and out-comes and subsequent challenges for pharmaceutical policy, with a special reference to Greece. Hippokratia 2014; 18(2): 100–6.
Leopold C, Mantel-Teeuwisse AK, Vogler S, Valkova S, de Joncheere K, Leufkens HG, et al. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bull World Health Organ 2014; 92(9): 630–640D.
Papaioannidou P, Ntaralas A. Attitudes in Antidepressants Use in Greece. Pharmacoepidemiol Drug Saf 2014; 23(S1): 115–6.
Papaioannidou P, Ntaralas A. Generic Use In Statin Sales In The Community of Thessaloniki, Greece. Clin Ther 2015; 37(8S): e148 ̶ 9.
World Health Organization. Guidelines for ATC classification and DDD assignment. 2015. [cited 2015 Sep 8]. Available from: http://www.whocc.no/atc_ddd_publications/guidelines/
NICE CG 178. Psychosis and schizophrenia in adults: Treat-ment and management. 2014. [cited 2015 Sep 8]. Available from: https://www.nice.org.uk/guidance/cg178/ re-sources/guidance-psychosis-and-schizophrenia-in-adults-treatment-and-management-pdf
Leiderman EA, Lorenzo L. Prescription patterns in the treat-ment of schizophrenia. Vertex 2015; 26(119): 11 ̶ 6. (Spanish)
Leopold C, Zhang F, Mantel-Teeuwisse AK, Vogler S, Valkova S, Ross-Degnan D, et al. Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: Interrupted time series analyses. Int J Equity Health 2014; 13: 53.
Jarema M, Meder J, Araszkiewicz A, Tyszkowska M. Antipsychotics in clinical practice. Treatment of the first schizophrenic episode. Psychiatr Pol 2008; 42: 841 ̶ 58. (Polish)
Meder J, Tyszkowska M, Jarema M, Araszkiewicz A, Szafrański T. Antipsychotics in clinical practice. The refractory schizophren-ic patients treatment. Psychiatr Pol 2008; 42(6): 859–73. (Polish)
Apiquian R, Fresán A, de la Fuente-Sandoval C, Ulloa RE, Nicolini H. Survey on schizophrenia treatment in Mexico: Perception and antipsychotic prescription patterns. BMC Psy-chiatry 2004; 4: 12.
Papaioannidou P, Ntaralas A. Generic use in antidepressant sales in Greece. J Bas Clin Pharmacol Toxicol 2014; 115(S1): 70.
Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther 2011; 17(6): 750–60.
Papaioannidou P, Kasviki P, Moschopoulos NP, Nimatoudis I. Anti-psychotic Prescribing in a Tertiary Hospital Under the Finan-cial Crisis in Greece. Pharmacoepidemiol Drug Saf 2016; 25(S3): 668.
Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev 2011; 4(2): 69–79.
Papaioannidou P, Kasviki P. Utilization of Antipsychotics in Eastern Thessaloniki and Kalamaria. Rev Clin Pharmacol Pharmacikinetics 2015; 29: 119–23.
Papaioannidou P, Michailidou M, Ntaralas A. Attitudes in statins use in Greece. Pharmacoepidemiol Drug Saf 2015; 24(S1): 144.
Papaioannidou P, Michailidou M, Ntaralas A, Michailidou S. Use of Antidepressants Under the Financial Crisis in Greece. Phar-macoepidemiol Drug Saf 2016; 25(S3): 665–6.